HIV associated nephropathy epidemiology and demographics: Difference between revisions
m Changes made per Mahshid's request |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Epidemiology== | ==Epidemiology== | ||
===Prevalence=== | ===<s>Prevalence</s>=== | ||
The prevalence of HIV-associated nephropathy in the | The prevalence of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported as 3% to 12%. | ||
===Incidence=== | <s>The prevalence of HIV-associated nephropathy in the United States and in Western European countries is estimated to range form 3 to 12 percent each year. The prevalence rate of HIV-associated neohropathy in children is estimated to be 10 to 15 percent each year. Though, there has been a decline in the incidences of HIV-associated nephropathy thank in part to the advent of HAART theraphy, which prolongs renal survival time.</s> | ||
The incidence of HIV-associated nephropathy in the United States is estimated to be around 800 to 900 new cases per year. | |||
===<s>Incidence</s>=== | |||
<s>The incidence of HIV-associated nephropathy in the United States is estimated to be around 800 to 900 new cases per year.</s> | |||
==Demographics== | ==Demographics== | ||
===Age=== | ===Age=== | ||
The average age at which patients are affected with HIV-associated nephropathy has been reported to be around 40.8 years of age in a study. | |||
===Gender=== | ===Gender=== | ||
HIV-associated nephropathy affects more | HIV-associated nephropathy affects men more than women. | ||
===Race=== | ===Race=== | ||
HIVAN is mostly seen in patients of African descent. | |||
==References== | ==References== | ||
Revision as of 16:43, 28 June 2020
|
HIV associated nephropathy Microchapters |
|
Differentiating HIV associated nephropathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV associated nephropathy epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of HIV associated nephropathy epidemiology and demographics |
|
FDA on HIV associated nephropathy epidemiology and demographics |
|
CDC on HIV associated nephropathy epidemiology and demographics |
|
HIV associated nephropathy epidemiology and demographics in the news |
|
Blogs on HIV associated nephropathy epidemiology and demographics |
|
Risk calculators and risk factors for HIV associated nephropathy epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]
Overview
Epidemiology
Prevalence
The prevalence of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported as 3% to 12%.
The prevalence of HIV-associated nephropathy in the United States and in Western European countries is estimated to range form 3 to 12 percent each year. The prevalence rate of HIV-associated neohropathy in children is estimated to be 10 to 15 percent each year. Though, there has been a decline in the incidences of HIV-associated nephropathy thank in part to the advent of HAART theraphy, which prolongs renal survival time.
Incidence
The incidence of HIV-associated nephropathy in the United States is estimated to be around 800 to 900 new cases per year.
Demographics
Age
The average age at which patients are affected with HIV-associated nephropathy has been reported to be around 40.8 years of age in a study.
Gender
HIV-associated nephropathy affects men more than women.
Race
HIVAN is mostly seen in patients of African descent.